Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) EBIT: 2023-2024

Historic EBIT for Pyxis Oncology (PYXS) over the last 2 years, with Dec 2024 value amounting to -$89.5 million.

  • Pyxis Oncology's EBIT rose 1.23% to -$23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$106.2 million, marking a year-over-year change of. This contributed to the annual value of -$89.5 million for FY2024, which is 8.84% down from last year.
  • Pyxis Oncology's EBIT amounted to -$89.5 million in FY2024, which was down 8.84% from -$82.2 million recorded in FY2023.
  • Over the past 5 years, Pyxis Oncology's EBIT peaked at -$82.2 million during FY2023, and registered a low of -$89.5 million during FY2024.
  • Its 2-year average for EBIT is -$85.8 million, with a median of -$85.8 million in 2023.
  • Data for Pyxis Oncology's EBIT shows a maximum YoY fell of 8.84% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Pyxis Oncology's EBIT stood at -$82.2 million in 2023, then decreased by 8.84% to -$89.5 million in 2024.